|
Hayer S., Toshidast-Akrad M., Haralambous S. Jahn-Schmid B., Skriner K., Trembleau S., Dumortier H., Pinol-Roma S., Redlich K., Schett G., Muller S. Kollias G., Smolen J. and Steiner G. (2005). Aberrant Expression of the Autoantigen Heterogeneous Nuclear Ribonucleoprotein-A2 (RA33) and Spontaneous Formation of Rheumatoid Arthritis-Associated Anti-RA33 Autoantibodies in TNF-α Transgenic Mice. J. Immunology, 175: 8327-8336.
Tseveleki V, Bauer J, Taoufik E, Ruan C, Leondiadis L, Haralambous S, Lassmann H & Probert L (2004). c-FLIPL overexpression in T cells is sufficient to drive Th2 effector responses and immunoregulation of experimental autoimmune encephalomyelitis. J Immunology, 173: 6619-6626.
Akassoglou K, Adams R, Bauer J, Mercado P, Tseveleki V, Probert L, Lassmann H & Strickland S (2004). Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. USA, 101: 6698-6703.
Tsagozis P, Tseveleki V, Probert L, Dotsika E & Karagouni K (2004). Vaccination with plasmids encoding the Leishmania major gp63 glycoprotein and CD40L results in a partial suppression of the inflammatory reaction after experimental infection. Eur. J. Inflammation 2(2): 91-96.
Hukkanen M, Platts LA, Haralambous S, Ainola M, Konttinen YT, Kollias G & Polak JM (2003). Induction of inducible nitric oxide synthase, argininosuccinate synthase, GTP cyclohydrolase I in arthritic joints of human tumor necrosis factor-alpha transgenic mice. J. Rheumatol. 30: 652-659.
Douni E, Sfikakis P, Haralambous S, Fernandez P & Kollias G (2003). Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res. Ther. 6 (1): R65-R72.
Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G & Probert L (2003). Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischaemia in the CNS of transgenic mice. Proc. Natl. Acad. Sci. USA, 100(2): 709-714.
Aidinis V, Plows D, Haralambous S, Armaka M, Papadopoulos P, Kanaki MZ, Koczan D, Thiesen HJ & Kollias G (2003). Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res. Ther. 5: R140-R157.
Tselios T, Apostolopoulou V, Daliani I, Deraos S, Grdadolnik S, Mavromoustakos T, Melachrinou M, Thymianou S, Probert L, Mouzaki A, Matsoukas J (2002). Antagonistic effectes of human cyclic MBP (87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J. Med. Chem. 45(2): 275-283.
Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Piestschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G. (2002). Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46: 785-792.
Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, Kainberger F, Haralambous S, Kollias G, Newby AC, Xu Q, Steiner G & Smolen J (2001). Adenovirus-based overexpression of tissue inhibitor of metalloproteinase 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. 44: 2888-2898.
Probert L & Akassoglou K (2001). Glial expression of cytokines in transgenic animals- how do these models reflect the “normal situation”. Invited Review. Glia , 36, 212-219.
Probert L, Eugster H-P, Akassoglou K, Bauer J, Frei K, Lassmann H & Fontana A (2000). TNFR1signalling is critical for demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Review, Brain, 123, 2005-2019.
Tselios T, Probert L, Kollias G, Daliani I, Matsoukas E, Troganis A, Gerothanassis IP, Mavromoustakos T, Moore GJ & Matsoukas JM (1999). Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: Importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J. Med. Chem. 42: 1170-1177.
Neurath MF, Hildner K, Becker C, Schlaak JF, Barbulescu K, Germann T, Schmitt E, Schirmacher P, Haralambous S, Pasparakis M, Meyer Zum Buschenfelde KH, Kollias G & Marker-Hermann E. (1999). Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115: 42-55.
Kassiotis G, Pasparakis M, Kollias G & Probert L (1999).TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunology 29: 774-780.
Kassiotis G, Bauer J, Akassoglou K, Lassmann H, Kollias G & Probert L (1999). A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. Eur. J. Immunology 29: 912-917.
Glosli H, Veiby OP, Fjerdingstad H, Mehlum A, Probert L, Kollias G, Gjernes E, Prydz H. (1999). Effects of hTNF alpha expression in T cells on haematopoiesis in transgenic mice. Eur. J. Haematol. 63: 50-60.
Aloe L, Properzi F, Probert L, Akassoglou K, Kassiotis G, Micera A & Fiore M (1999). Learning abilities, NGF and BDNF brain levels in two lines of TNF-α transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Research 840: 125-137.
Aloe L, Fiore M, Probert L, Turrini P & Tirassa P (1999). Overexpression of tumour necrosis factor alpha in the brain of transgenic mice differentially alters nerve growth factor levels and choline acetyltransferase activity. Cytokine 11: 45-54.
Akassoglou K, Bauer J, Kassiotis G, Lassmann H, Kollias G & Probert L (1999). Transgenic models of TNF induced demyelination. Adv. Exp. Med. Biol. 468: 245-259.
Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V & Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187: 461-468.
Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G & Probert L (1998). Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the CNS of transgenic mice: Models for Multiple Sclerosis with primary oligodendropathy. Am. J. Pathol. 153: 801-813.
Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L & Kollias G (1997) TNF alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol. 72 137-141. Review.
Probert L & Selmaj K (1997) TNF and related molecules: Trends in neuroscience and clinical applications. J Neuroimmunol. 72: 113-117. Review.
Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, Strober W & Kollias G (1997). Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27: 1743-1750.
Cope AP, Liblau RS, Yang X-D, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G & McDevitt HO (1997) Chronic tumor necrosis factor (TNF) alters T cell responses by attenuating T cell receptor signalling. J. Exp. Med. 185: 1573-1584.
Akassoglou K, Probert L, Kontogeorgos G & Kollias G (1997) Astrocyte- but not Neuron-Specific Transmembrane TNF Triggers Inflammation, Demyelination and Neuronal Degeneration in the CNS of Transgenic Mice. J. Immunol. 158: 438-445.
Probert L, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D & Kollias G (1996) Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J. Leuk. Biol. 59: 518-525. Review.
Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L & Kollias G (1996) Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J. Inflammation 47: 27-38. Review.
Siegel SA, Shealy DJ, Nakada MT, Le J, Wolfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J & Daddona PE (1995) The mouse/human chimeric monoclonal antibody Ca2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7: 15-25. *Pre-clinical trial of Ca2 anti-TNF antibody now used in RA patients.
Probert L, Plows D, Kontogeorgos G & Kollias G. (1995) The type I IL-1 receptor acts in series with TNF to induce arthritis in TNF transgenic mice. Eur. J. Immunol. 25: 1794-1797.
Probert L, Akassoglou K, Pasparakis M, Kontogiorgos G & Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing CNS-specific expression of tumor necrosis factor. Proc. Natl. Acad. Sci. USA 92: 11294-11298.
Mappouras DG, Philippou G, Haralambous S, Tzartos SJ, Balafas A, Souvatzoglou A & Lymberi P (1995). Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Grave’s disease. Clin. Exp. Immunol. 100: 336-343.
Haralambous S, Blackwell C, Mappouras DG, Weir DM, Kemmett D & Lymberi P (1995). Increased natural autoantibody activity to cytoskeleton proteins in sera from patients with necrobiosis lipoidica, with or without insulin-dependent diabetes mellitus. Autoimmunity 20: 267-275.
Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D & Kollias G (1993). Wasting, ischaemia and lymphoid abnormalities in mice expressing T cell-targeted human tumour necrosis factor transgenes. J. Immunology 151: 1894-1906.
Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D & Kollias G (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO Journal 10: 4025-4031. *Selected as a classic paper in Rheumatoid Arthritis, PPS Europe Ltd, 1994 . |